secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alaunos Therapeutics, Inc. (TCRT)
CIK:        0001107421
Form:       8-K
Filed at:   2026-03-02T23:59:59+00:00
Accession:  0001193125-26-084084
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alaunos reports positive preclinical data for ALN1003; weight loss up to 12.9% in DIO mice
--------------------------------------------------------------------------------

- ALN1003 showed dose-dependent body weight loss: -12.9% peak (Day 34) and -10.3% after 48 days vs DIO control (p<0.0001).
- Liver weight reduced 43% (p<0.0001); liver enzymes ALT, AST, ALP significantly decreased in Study 1.
- Highest-dose group lowered glucose to 197 mg/dL (vs 320 control) and total cholesterol to 162 mg/dL (vs 209).
- Cash and equivalents ~$1.9M as of Sept 30, 2025; runway into Q2 2026; additional financing being pursued.
- ALN1003 is an oral non-hormonal small molecule; company planning IND-enabling studies and next-gen compounds.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1107421/000119312526084084/0001193125-26-084084-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1107421/000119312526084084/tcrt-20260302.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-084084

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer